Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne and Regulus Therapeutics have announced the continuation of their technical and clinical collaboration following positive topline results from the second cohort of Regulus' Phase 1B study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease.
May 22, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics announced positive topline results from the second cohort of its Phase 1B study of RGLS8429, leading to the continuation of its collaboration with Bio-Techne.
Positive clinical trial results are likely to boost investor confidence in Regulus Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Bio-Techne continues its collaboration with Regulus Therapeutics following positive results from the Phase 1B study of RGLS8429.
The continuation of the collaboration with Regulus Therapeutics following positive trial results is a positive development for Bio-Techne, likely to have a favorable impact on its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80